CEA is an Independent Prognostic Indicator that is Associated with Reduced Survival and Liver Metastases in SCLC
CEA is an Independent Prognostic Indicator that is Associated with Reduced Survival and Liver Metastases in SCLC
复制标题
CEA 是一种独立的预后指标，与 SCLC 的生存率降低和肝转移相关
DOI：
10.1007/s12013-010-9121-0
复制
发表时间：
2011-03-01
影响因子：
2.6
通讯作者：
Wang, Zhengbo
中科院分区：
文献类型：
--
作者：
Yang, Xueqin;Wang, Dong;Wang, Zhengbo
小细胞肺癌（SCLC）分为两个阶段，局限性小细胞肺癌（LS-SCLC）和广泛期小细胞肺癌（ES-SCLC），其中ES-SCLC与生存率降低有关。然而，仅疾病阶段并不能非常精确地预测生存时间。本研究的目的是寻找可与 SCLC 分期系统结合使用的预后指标。我们对 116 名接受标准化疗（联合或不联合放疗）的 SCLC 患者进行了前瞻性分析。在诊断时通过商业蛋白质芯片系统测量 12 种肿瘤标志物的表达水平，并对患者进行最长 54 周的随访。 CEA 是 SCLC 中最常检测到的肿瘤标志物，32.8% 的样本呈阳性，也是唯一与总生存期相关的标志物。 CEA 低于 5 ng/ml 的患者的平均生存时间为 16.78 个月，CEA 高于 5 ng/ml 的患者的平均生存时间为 11.4 个月（P<0.001）。相反，没有发现肿瘤分期和总生存率之间存在关联。 CEA 表达与肿瘤分期无关 (P= 0.930)。 CEA 是一个独立的预后因素，可与 SCLC 的疾病分期结合使用。
Small-cell lung cancer (SCLC) is classified into two stages, limited-stage small-cell lung cancer (LS-SCLC) and extensive-stage small-cell lung cancer (ES-SCLC), with ES-SCLC being associated with reduced survival. However, disease stage alone is not a very precise predictor of survival time. The aim of this study is to search for a prognostic indicator that can be used in conjunction with the staging system in SCLC. We performed a prospective analysis of 116 patients with SCLC undergoing standard chemotherapy with or without radiotherapy. Expression levels of 12 tumor markers were measured at the time of diagnosis by a commercial protein chip system, and patients were followed up for a maximum of 54 weeks. CEA was the most frequently detected tumor marker in SCLC, with 32.8% of samples scoring positive, and was also the only marker that correlated with overall survival. The average survival time was 16.78 months for patients with CEA below 5 ng/ml and 11.4 months for patients with CEA above 5 ng/ml (P< 0.001). In contrast, no association was found between tumor stage and overall survival. CEA expression was independent of tumor stage (P= 0.930). CEA is an independent prognostic factor that can be used in conjunction with disease stage in SCLC.